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Dedication ((optional)) 
 We describe a flexible and high yielding synthesis of 1,3-
disubstituted ureas,
1
that allows for the construction of both 
symmetrical and unsymmetrical dipeptide ureas, including easy 
access to 
13
C labelled ureas, from amino acids and carbon 
dioxide at atmospheric pressure. 
Introduction 
The usefulness of ureas in materials chemistry,
1,2,3
 
pharmaceutical chemistry,
4–6
 and biology
7,8
 is evident from the 
publication of many more than a thousand papers reporting their 
synthesis and applications. These diverse series of compounds 
have wide series of applications ranging from plasticisers to 
pharmaceuticals. Importantly, ureas are also a key component 
of several bioactive natural products (Figure 1),
9
 including 
mozamide A (1), oscillamide Y (2) and the uridyl peptide 
antibiotics (of which pacidamycin 4 (3) is a member).
10–12
 In the 
uridyl peptide series of antibiotics the incorporation of a 
diaminoacid N to N inverts the sense of the peptide, the N to C 
directionality is restored by the incorporation of a urea; this 
double inversion in the sense of the peptide potentially confers a 
level of resistance to degradation by proteases.
12
 
 
The vast majority of methods to synthesise ureas rely upon the 
use of phosgene or isocyanates as staring materials
13–20
 
Alternatively, approaches based on activated carbamates which 
can be generated from various carbonylation reagent such as 
carbonates
21
 chloroformates
22
 and N,N-carbonyldiimidazole 
(CDI)
23
  have been described for the synthesis of peptide ureas. 
Newer methods have been developed using carbon monoxide or 
carbon dioxide with transition metal catalysts.
24–27
 These 
procedures are generally accompanied by the disadvantage that 
they require either the use of very high temperatures or 
pressures, expensive catalysts, highly specialised apparatus or 
do not afford the flexibility to synthesise unsymmetrical ureas.  
 
 
 
Figure 1. Urea-containing natural products. Mozamide A (1), oscillamide Y (2) 
and pacidamycin 4 (3), the urea moiety is highlighted. 
Herein, we describe a simple procedure that allows for the ready 
formation of symmetrical and unsymmetrical ureas from amino 
acids or amines and carbon dioxide. 
Results and Discussion 
Our simple one-pot, sequential, low temperature and 
atmospheric pressure route to ureas is inspired by the work of 
McGhee et al.,
28
 which involves first the deprotonation of an 
amine with base and reaction with carbon dioxide to form the 
carbamate anion, followed by its conversion to an isocyanate 
using thionyl chloride (Scheme 1).  
Scheme 1. Conversion of amines to isocyanate using thionyl chloride.
28
 
The utility of this route to access carbamates has been elegantly 
demonstrated by Taylor et al.
29,30
 In the present work, once the 
isocyanate is formed, by removal of the solvent and all volatiles, 
in vacuo, re-dissolving the residue in pyridine and then 
introducing a second amino acid, we demonstrated that ready 
access to the  urea formation could be afforded. This approach 
enabled us to access a series of 1,3-disubstituted urea 
analogues (Scheme 2).  
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Scheme 2. Synthesis of unsymmetrical 1,3-disubstituted ureas. 
Firstly, optimisation of the reaction conditions was carried out by 
exploring the synthesis of the unsymmetrical alanine-urea-
tryptophan (4) as a model system. Dried carbon dioxide, 
generated from CO2(s) was bubbled into a cooled solution of 
ʟ-alanine benzyl ester p-toluenesulfonate in dichloromethane 
(DCM) with 1,8-diazabicycloundec-7-ene (DBU) and pyridine. It 
is noteworthy that DBU facilitates the formation and stabilisation 
of the carbamate anion adduct of the amine with CO2(g), whereas 
pyridine liberates  the free amine from its p-toluenesulfonate salt. 
Thionyl chloride was then added and the reaction was allowed to 
warm to room temperature. Volatiles were removed under 
reduced pressure, anhydrous pyridine was added to solvate the 
isocyanate, and then ʟ-tryptophan methyl ester was added as a 
solution in anhydrous pyridine. Using this pre-optimized method, 
next, the effect of altering temperature and reagent 
concentrations was systematically investigated. This screening 
revealed that the temperature at which the carbon dioxide and 
thionyl chloride are added have a great impact on the overall 
yield (Table 1). Under the same reaction conditions, low yields 
were obtained at -10ºC and -50ºC (Table 1, entries 2 and 15 
respectively). A slightly increase in the total yield was afforded at 
-30ºC (Table 1, entry 13) but, to our delight, when the reaction 
was performed at -20ºC the yield dramatically increased to 74% 
(Table 1, entry 6). The need for the subtle tuning of temperature 
is curious and can perhaps be explained by low reactivity and/or 
solubility of the reactants at -30ºC, balanced against the 
instability and decomposition of intermediates at the higher 
temperature of -10ºC. 
 
Keeping -20ºC as the optimal temperature, we then studied the 
effect of the concentration of reagents. We found that for DBU, 
the best yield was obtained upon using 5 eq since, under the 
same reaction conditions, neither the use of an increased 
amount (8 eq) nor a decreased amount (3 eq) was beneficial to 
the overall reaction yield (Table 1, entries 6, 7 and 8 
respectively). In the case of pyridine, the optimal quantity was 
found to be 3 eq. since increased amounts (4 and 5 eq) resulted 
in very poor yields (Table 1 entries 6, 9 and 10 respectively). 
This effect could be attributed to the reaction of the overexcess 
base with SOCl2, thus lowering the concentration of the later for 
the generation of the desired isocyanate. Addition of 1.5 eq of 
SOCl2 was enough to afford high yields of the desired urea 
compound (Table 1, entry 6). Upon using a larger excess of this 
reagent (2 and 3 eq) the obtained yields were comparable 
(Table 1, entries 11 and 12 respectively). It is important to note 
that a high excess of SOCl2 resulted in a very dark reaction 
mixture and further problems in the workup procedure. Thus, 1.5 
eq of SOCl2 was determined as the optimal amount as 
demonstrated through the reactions reported in Table 1. 
 
Depending upon reagent availabilities, rather than generate the 
CO2(g) from CO2(s),  dry CO2(g) from a cylinder can be directly 
used.  We noted that upon using a CO2(g) cylinder an  
improvement of 10% in yield was obtained (Table 1, entry 6 was 
elevated from 74 to 85% yield).  
 
Finally, we explored the effect of replacing thionyl chloride with 
p-toluenesulfonyl chloride (p-TsCl) or 
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU) as alternative 
activators (Table 2). In all cases, formation of the desired 
product was observed but generally the isolated yields were 
considerably lower, even upon using larger excess, in 
comparison to the use of SOCl2 (Table 2, entries 2 to 6 and 1 
respectively). 
 
Table 1. Reaction optimisation. Compound 4, aa1 = Ala, aa2 = Trp  
 
 
 
 
 
Entry Temp, ºC DBU, eq Pyridine, 
eq 
SOCl2, 
eq 
Yield,
 
%
[a],[b]
 
1 -10 3 2 1.5 15 
2 -10 5 3 1.5 22 
3 -10 5 3 3 28 
4 -10 3 2 1.5 22 
5 -10 5 2 1.5 35 
6 -20 5 3 1.5 74 
7 -20 8 3 1.5 20 
8 -20 3 3 1.5 69 
9 -20 5 4 1.5 8 
10 -20 5 5 1.5 6 
11 -20 5 3 2 73 
12 -20 5 3 3 76 
13 -30 5 3 1.5 40 
14 -30 5 3 3 42 
15 -50 5 3 1.5 15 
[a] Reactions were carried out using alanine benzyl ester p-toluenesulfonate (1 
eq) and tryptophan methyl ester hydrochloride (1 eq) in DCM as specified 
above. [b] Isolated are reported after flash chromatography 
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Table 2. Screening of alternative activators for synthesis of 
compound 4. aa1 = Ala, aa2 = Trp 
Entry Activator eq Yield, %
[a],[b]
 
1 SOCl2 1.5 74 
2 p-TsCl 1.5 28 
3 p-TsCl 2 35 
4 p-TsCl 3 30 
5
[c]
 HATU 1.5 45 
6 HATU 2 48 
[a] Reactions were carried out using alanine benzyl ester 
p-toluenesulfonate (1 eq), tryptophan methyl ester 
hydrochloride (1 eq), DBU (5 eq), pyridine (3 eq) in DCM at -
20ºC as specified above. [b] Isolated yields are reported 
after flash chromatography. [c] A slightly different procedure 
was used, see experimental section. 
 
Using the optimized conditions with thionyl chloride, access to 
symmetrical ureas was shown to be particularly high yielding, 
over 90% in all cases (Table 3, entries 1-3).  
 
Table 3. One-pot synthesis of symmetrical urea analogues, aa1=aa2. 
 
 
 
 
Entry R1 R2 aa1=aa2 Yield, %
[a],[b]
 
1 Me Bn Phe 96± 0.03 (5) 
2 Me CH2CH2SCH3 Met 93± 0.1 (6) 
3 Bn Me Ala 95± 0.07 (7) 
[a] Reactions were carried out using aa1 (1 eq), aa2 (1 eq), DBU (5 eq), 
pyridine (3 eq) and SOCl2 (1.5 eq) in DCM as specified above. [b] Isolated 
yields are reported after flash chromatography from reactions carried out in 
triplicate. 
 
Encouraged by these results, we next focused on expanding the 
scope of the reaction on the synthesis of unsymmetrical ureas. A 
series of six methyl ester and benzyl ester protected amino 
acids were synthesised and using these, a range of ureas were 
prepared in modest to good yields (Table 4, entries 1-11). 
 
As shown in Table 4, reacting Ala as aa1 with Trp (Tryptophan), 
Phe (Phenylalanine) and Met (Methionine) as aa2 afforded high 
yields of the corresponding 1,3-disubstituted urea analogues 
(Table 4, entries 1, 2 and 3).  
Notably, the coupling of Ala as aa1 with halogenated Trp 
(generated by biocatalysis through a well established protocol 
previously developed in our group)
31,32
 as aa2 also afforded the 
corresponding desired urea analog with moderate yields (Table 
4, entries 4 to 7).  
 
 
Table 4. One-pot synthesis of unsymmetrical urea 
analogues. 
 
Entry aa1 aa2 Yield, %
[a],[b]
 
1 Ala Trp 74 ± 0.8 (4) 
2 Ala Phe 78 ± 0.5 (8) 
3 Ala Met 68 ± 1.0 (9) 
4 Ala 5-Br-Trp 55 ± 0.8 (10) 
5 Ala 5-Cl-Trp 52 ± 1.1 (11) 
6 Ala 5-F-Trp 58 ± 0.5 (12) 
7 Ala 7-I-Trp 72 ± 0.9 (13) 
8 Met Phe 60 ± 0.7 (14) 
9 Met Trp 63 ± 0.5 (15) 
10 Leu Phe 55 ± 0.9 (16) 
11 Leu Met 40 ± 1.2 (17) 
12 Ala (
13
CO2) Trp 90 (18) 
[a] Reactions were carried out using aa1 (1 eq), aa2 (1 eq), 
DBU (5 eq), pyridine (3 eq) and SOCl2 (1.5 eq) in DCM as 
specified above. [b] Isolated yields are reported after flash 
chromatography from reactions carried out in triplicate. 
 
Changing aa1 to Leu (Leucine) and Met successfully resulted in 
the formation of the desired urea product but in lower yields 
(Table 4, entries 8-10 respectively). This decrease in yield upon 
changing aa1 could be explained mainly due to the steric effects 
of the side chain in α position (R1).  
 
Remarkably, in all cases, this one-pot method is highly 
reproducible as shown by the very low error obtained from 
performing the reactions in triplicate.  
 
Most importantly, using 
13
C carbon dioxide we successfully 
generated isotopically labelled urea in almost a quantitively 
manner (Table 4, entry 12). The obtained higher yield over the 
unlabelled system (90% and 74% respectively) can be 
rationalised by the fact that rigorously dry 
13
CO2(g) was provided 
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directly from a gas cylinder rather from simply evaporating and 
drying CO2(s). 
Conclusions 
In summary, we have developed a simple and efficient synthetic 
approach enabling easy access to symmetrical and the more 
challenging unsymmetrical 1,3-disubstiuted ureas from amino 
acids and carbon dioxide in moderate to high yields at 
atmospheric pressure. Moreover, the utility of this one-pot 
approach for accessing 
13
C labelled urea has also been 
demonstrated. Although the current methodology is applied to 
the synthesis of dipeptide ureas, in principle, it could potentially 
be extended to other types of building blocks to generate 1,3 
disubstituted ureas apart from amino acids.  
 
Experimental Section 
General experimental methods: TLC analysis was carried out on Merck 
aluminium-backed silica gel 60 F254 and was visualised by ultraviolet light 
(UV) using a model UVGL-58 MINERLIGHT® LAMP multiband UV-
254/365 nm, by ninhydrin stain (50 mg of ninhydrin dissolved in 40 ml of 
acetone). Column chromatography was carried out on Davisil® 
chromatographic silica media LC60A 40-63μm. Anhydrous DCM was 
obtained using a MBRAUN SPS 800 filtered over pre-packed alumina 
columns. Anhydrous pyridine was distilled over calcium hydride under 
argon atmosphere and stored over activated 4 Å molecular sieves. 
Anhydrous DMF was purchased. All other solvents were SLR grade and 
used without further purification unless stated otherwise. When 
anhydrous solvents were used, all glassware was oven dried and cooled 
under argon. L-7-Iodotryptophan, L-5-bromotryptophan, L-5-
chlorotryptophan, and L-5-fluorotryptophan were prepared as previously 
described. 31,32 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-tryptophan 
methyl ester (4): 
Dry ice was placed in a 500 ml round-bottom flask connected to a 
paraffin oil bubbler then to a drying tube containing pellets of activated 4 
Å molecular sieves.  Using the Teflon tubing, CO2 (g) derived from dry ice 
was bubbled into a stirred solution of L-alanine benzyl ester p-
toluenesulfonate salt (0.20 g, 0.57 mmol), 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (0.43 ml, 2.85 mmol) and pyridine (0.14 ml, 1.71 mmol) in 
anhydrous DCM (30 ml) at -20 C, for a period of 30 minutes whilst 
keeping the mixture at -20 C. Subsequently, a solution of thionyl chloride 
(0.08 ml, 1.14 mmol) in anhydrous DCM (5 ml) was carefully added to the 
reaction over a period of 20 minutes under an atmosphere of argon. The 
reaction was then left stirring under an atmosphere of argon for 2 hours 
while it was allowed to warm up to room temperature. Upon addition of 
thionyl chloride, the color of the reaction mixture gradually changed from 
clear to yellow to brown as the reaction warms up to room temperature. 
Afterwards, the solvent was removed under reduced pressure and the 
brown, oily residue was dissolved in anhydrous pyridine (8 ml). Under an 
atmosphere of argon, a solution of L-tryptophan methyl ester 
hydrochloride salt (0.15 g, 0.57 mmol) in anhydrous pyridine (2 ml) was 
added over a period of 10 minutes at room temperature. The mixture was 
left stirring under an atmosphere of nitrogen at room temperature for 4 
hours. The solvent was then removed under reduced pressure and the 
brown residue was dissolved in ethyl acetate (50 ml) and washed five 
times with a saturated sodium bicarbonate solution (40 ml). The organic 
layer was dried over magnesium sulfate, filtered, concentrated under 
reduced pressure and purified using flash chromatography (SiO2, hexane 
/ ethyl acetate 3:1 to 1:1, ninhydrin/UV) to yield the target compound 
(4)(0.19 g, 0.44 mmol, 74%) as a white powder.  
1H NMR (500 MHz, CDCl3) 8.62 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.29 – 
7.36 (m, 4H), 7.19 – 7.21 (m, 2H), 7.15 (t, J = 7.6 Hz, 1H), 7.07 (t, J = 7.4 
Hz, 1H), 6.87 (s, 1H), 5.78 (d, J = 8.4 Hz, 1H), 5.64 (d, J = 8.0 Hz, 1H), 
5.06 (d, J = 12.3 Hz, 1H), 4.85 (dt, J = 7.9, 5.3 Hz, 1H), 4.72 (d, J = 12.3 
Hz, 1H), 4.64 (p, J = 7.4 Hz, 1H), 3.62 (s, 3H), 3.28 (dd, J = 14.8, 5.3 Hz, 
1H), 3.18 (dd, J = 14.8, 5.1 Hz, 1H), 1.30 (d, J = 7.3 Hz, 3H); 13C-NMR 
(126 MHz, CDCl3)  175.0, 173.4, 156.8, 135.9, 135.2, 128.5, 128.3, 
128.1, 127.4, 123.6, 121.9, 119.3, 118.4, 111.4, 109.2, 67.2, 53.1, 52.3, 
48.5, 28.0, 19.0; HRMS (ESI, +ve) C23H25N3O5 [M+Na]
+ calculated for 
446.1679, found 446.1680. 
N,N’-Carbonyl bis(L-phenylalanine methyl ester) (5): 
N,N’-Carbonyl bis(L-phenylalanine methyl ester) (5) (0.09 g, 0.23 mmol, 
96%), white powder, was prepared following the same procedure as 
described for compound (4) 
1H NMR (500 MHz, CDCl3)  7.20 – 7.30 (m, 6H), 7.09 (d, J = 7.1 Hz, 4H), 
5.51 (d, J = 8.4 Hz, 2H), 4.82 (dt, J = 8.4, 5.8 Hz, 2H), 3.63 (s, 6H), 3.00 
(d, J = 5.9 Hz, 4H); 13C NMR (126 MHz, CDCl3)  173.3, 156.2, 136.1, 
129.3, 128.4, 126.9, 53.9, 52.2, 38.7; HRMS (ESI, +ve) C21H24N2O5 
[M+H]+ calculated for 385.1758, found 385.1761. 
N,N’-Carbonyl bis(L-methionine methyl ester) (6): 
N,N’-Carbonyl bis(L-methionine methyl ester) (6) (0.16 g, 0.46 mmol, 
93%), white powder, was prepared following the same procedure as 
described for compound (4). 
1H NMR (500 MHz, CDCl3)  5.67 (d, J = 8.2 Hz, 2H), 4.60 (td, J = 7.7, 
5.0 Hz, 2H), 3.76 (s, 6H), 2.53 (t, J = 7.5 Hz, 4H), 2.06 – 2.17 (m, 8H), 
1.94 (dq, J = 14.6, 7.4 Hz, 2H); 13C NMR (126 MHz, CDCl3)  173.8, 
156.8, 52.5, 52.2, 32.3, 29.9, 15.4; HRMS (ESI, +ve) C13H24N2O5S2 
[M+H]+ calculated for 353.1199 found 353.1202. 
N,N’-Carbonyl-bis(L-alanine benzyl ester) (7): 
N,N’-Carbonyl bis(L-alanine benzyl ester) (7) (0.10 g, 0.27 mmol, 95%), 
white powder, was prepared following the same procedure as described 
for compound (4). 
1H NMR (500 MHz, CDCl3)  7.32 – 7.40 (m, 10H), 5.35 (d, J = 7.7 Hz, 
2H), 5.22 (d, J = 12.4 Hz, 2H), 5.15 (d, J = 12.4 Hz, 2H), 4.55 (p, J = 7.3 
Hz, 2H), 1.39 (d, J = 7.2 Hz, 6H); 13C NMR (126 MHz, CDCl3)  174.1, 
156.4, 135.4, 128.6, 128.3, 128.1, 67.0, 48.8, 18.9; HRMS (ESI, +ve) 
C21H24N2O5 [M+H]
+ calculated for 385.1758, found 385.1761. 
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N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-
phenylalanine methyl ester (8): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-phenylalanine 
methyl ester (8) (0.17 g, 0.42 mmol, 78%), white powder, was prepared 
following the same procedure as described for compound (4). 
1H NMR (500 MHz, CDCl3)  7.34 – 7.39 (m, 5H), 7.22 – 7.26 (m, 3H), 
7.11 (d, J = 7.1 Hz, 2H), 5.24 – 5.08 (m, 4H), 5.02 (d, J = 8.1 Hz, 1H), 
4.80 (dt, J = 5.7, 8.2 Hz, 1H), 4.50 – 4.58 (m, 1H), 3.71 (s, 3H), 3.09 (dd, 
J = 2.6, 5.8 Hz, 2H), 1.37 (d, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) 
 173.8, 172.9, 156.1, 135.9, 135.4, 129.3, 128.6, 128.5, 128.3, 128.1, 
127.0, 67.0, 53.8, 52.2, 48.8, 38.5, 19.0; HRMS (ESI, +ve) C21H24N2O5 
[M+Na]+ calculated for 407.1565, found: 407.1566. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-methionine 
methyl ester (9): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-methionine 
methyl ester (9) (0.15 g, 0.40 mmol, 68%), white powder, was prepared 
following the same procedure as described for compound (4). 
1H NMR (500 MHz, CDCl3) 7.30 – 7.40 (m, 5H), 5.57 (d, J = 8.1 Hz, 1H), 
5.48 (d, J = 7.7 Hz, 1H), 5.11 – 5.24 (m, 2H), 4.62 (td, J = 7.7, 4.9 Hz, 
1H), 4.51 – 4.58 (m, 1H), 3.76 (s, 3H), 2.53 (t, J = 7.5 Hz, 2H), 2.06 – 
2.16 (m, 4H), 1.93 (dq, J = 14.6, 7.4 Hz, 1H), 1.39 (d, J = 7.1 Hz, 3H); 
13C NMR (126 MHz, CDCl3)  174.0, 173.9, 156.6, 135.4, 128.6, 128.3, 
128.0, 67.0, 52.5, 52.2, 48.9, 32.3, 29.9, 18.9, 15.4; HRMS (ESI, +ve) 
C17H24N2O5S[M+Na]
+ calculated for 391.1292, found 391.1290. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]- 
L-5-bromotryptophan methyl ester (10): 
N-[[(1S)-
1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-5-bromotryptophan methyl 
ester (10) (0.08 g, 0.16 mmol, 55%), white powder, was prepared 
following the same procedure as described for compound (4). 
1H NMR (500 MHz, CDCl3)  8.74 (s, 1H), 7.58 (s, 1H), 7.31 – 7.35 (m, 
3H), 7.13 – 7.23 (m, 4H), 6.86 (s, 1H), 5.86 (d, J = 8.7 Hz, 1H), 5.67 (d, 
J = 7.9 Hz, 1H), 5.04 (d, J = 12.3 Hz, 1H), 4.83 (dt, J = 7.9, 5.0 Hz, 1H), 
4.63 – 4.73 (m, 2H), 3.68 (s, 3H), 3.21 (dd, J = 14.9, 5.0 Hz, 1H), 
3.12 (dd, J = 14.9, 5.0 Hz, 1H), 1.35 (d, J = 7.2 Hz, 3H); 13C NMR 
(126 MHz, CDCl3)  175.2, 173.0, 156.7, 135.0, 134.4, 129.1, 128.5, 
128.4, 128.0, 125.0, 124.7, 121.0, 112.8, 112.6, 108.8, 67.4, 52.9, 52.4, 
48.5, 27.9, 19.2; HRMS (ESI, +ve) C23H24BrN3O5 [M+Na]
+ calculated for 
524.0786, found 524.0788. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]- 
L-5-chlorotryptophan methyl ester (11): 
N-[[(1S)-
1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-5-chlorotryptophan methyl 
ester (11) (0.09 g, 0.2 mmol, 52%), white powder, was prepared following 
the same procedure as described for compound (4). 
1H NMR (400 MHz, CDCl3)  8.84 (s, 1H), 7.42 (d, J = 2.0 Hz, 1H), 7.30 – 
7.34 (m, 3H), 7.21 (d, J = 8.6 Hz, 1H), 7.13 – 7.20 (m, 2H), 7.07 (dd, 
J = 8.6, 2.0 Hz, 1H), 6.87 (d, J = 2.4 Hz, 1H), 5.97 (d, J = 7.9 Hz, 1H), 
5.77 (d, J = 7.9 Hz, 1H), 5.05 (d, J = 12.3 Hz, 1H), 4.84 (1 H, J = 7.9, 5.0 
Hz, dt), 4.61 – 4.74 (m, 2H), 3.66 (s, 3H), 3.21 (dd, J = 14.9, 5.1 Hz, 1H), 
3.11 (dd, J = 14.9, 5.0 Hz, 1H), 1.33 (d, J = 7.2 Hz, 3H); 13C NMR 
(101 MHz, CDCl3)  175.3, 173.1, 135.0, 134.2, 128.5, 128.4, 128.3, 
128.0, 125.2, 125.1, 122.1, 117.9, 112.4, 108.9, 67.4, 52.9, 52.4, 48.5, 
27.9, 19.1; HRMS (ESI, +ve) C23H24ClN3O5 [M+H]
+ calculated for 
458.1477, found 458.1478. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]- 
L-5-fluorotryptophan methyl ester (12): 
N-[[(1S)-
1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-5-fluorotryptophan methyl 
ester (12) (0.10 g, 0.23 mmol, 58%), white powder, was prepared 
following the same procedure as described for compound (4). 
1H NMR (400 MHz, CDCl3)  8.73 (s, 1H), 7.32 (m, 3H), 7.16 – 7.25 (m, 
3H), 7.10 (dd, J = 9.8, 2.6 Hz, 1H), 6.87 – 6.92 (m, 2H), 5.89 (d, J = 8.5 
Hz, 1H), 5.71 (d, J = 8.1 Hz, 1H), 5.07 (d, J = 12.4 Hz, 1H), 4.83 (dt, 
J = 8.0, 5.1 Hz, 1H), 4.75 (d, J = 12.4 Hz, 1H), 4.61 – 4.70 (m, 1H), 3.65 
(s, 3H), 3.20 (dd, J = 14.9, 5.1 Hz, 1H), 3.12 (dd, J = 14.9, 5.0 Hz, 1H), 
1.32 (d, J = 7.2 Hz, 3H); 13C NMR (101 MHz, CDCl3)  175.1, 173.2, 
156.8, 156.7 (d, J = 32.2 Hz), 133.8 (d, J = 277.9 Hz), 128.5, 128.3, 
128.0, 127.8 (d, J = 9.6 Hz), 125.5, 123.9, 112.04 (d, J  = 9.7 Hz), 110.30 
(d, J = 26.2 Hz), 109.37 (d, J = 4.7 Hz), 103.2 (d, J = 23.6 Hz), 67.3, 53.0, 
52.4, 48.5, 28.0, 19.1; 19F NMR (377 MHz, CDCl3, decoupled 
1H) 
  -124.89; 19F NMR (377 MHz, CDCl3, coupled 
1H)   -124.90 (td, J = 9.4, 
4.3 Hz); HRMS (ESI, +ve) C23H24FN3O5 [M+H]
+ calculated for 442. 7713, 
found 442.7768. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]- 
L-7-iodotryptophan methyl ester (13): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-7-iodotryptophan 
methyl ester (13) (0.11 g, 0.19 mmol, 72%), white powder, was prepared 
following the same procedure as described for compound (4). 
1H NMR (400 MHz, CDCl3)  8.64 (s, 1H), 7.50 (d, J = 7.5 Hz, 1H), 7.43 
(d, J = 7.9 Hz, 1H), 7.35 (m, 2H), 7.25 – 7.32 (m, 3H), 6.91 (d, J = 2.4 Hz, 
1H), 6.83 (t, J = 7.7 Hz, 1H), 5.79 (d, J = 8.1 Hz, 1H), 5.66 (d, J = 8.2 Hz, 
1H), 5.11 (d, J = 12.4 Hz, 1H), 4.91 (dt, J = 8.2, 5.0 Hz, 1H), 4.80 (d, 
J = 12.3 Hz, 1H), 4.70 (apparent p, J = 7.4 Hz, 1H), 3.59 (s, 3H), 3.23 (dd, 
J = 14.8, 4.9 Hz, 1H), 3.14 (dd, J = 14.9, 5.3 Hz, 1H), 1.29 (d, J = 7.2 Hz, 
2H); 13C NMR (101 MHz, CDCl3)  174.9, 173.3, 156.7, 137.8, 135.3, 
130.5, 128.6, 128.4, 128.1, 127.5, 124.1, 121.0, 118.6, 110.9, 76.7, 67.2, 
52.9, 52.3, 48.5, 28.5, 19.1; HRMS (ESI, +ve) C23H24IN3O5 [M+H]
+ 
calculated for 550.0833, found 550.0826. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4-(methylthio)propyl]-
aminocarbonyl]-L-phenylalanine methyl ester (14): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4-(methylthio)propyl]-
aminocarbonyl]-L-phenylalanine methyl ester (14) (0.07 g, 0.16 mmol, 
60%), white powder, was prepared following the same procedure as 
described for compound (4). 
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1H NMR (500 MHz, CDCl3)  7.36 – 7.41 (m, 5H), 7.25 – 7.29 (m, 3H), 
7.11 (d, J = 6.6 Hz, 2H), 5.23 (d, J = 12.2 Hz, 1H), 5.17 (d, J = 12.1 Hz), 
5.02 (d, J = 8.0 Hz, 1H), 4.87 (d, J = 8.0 Hz, 1H), 4.78 (dt, J = 7.9, 5.6 Hz, 
1H), 4.63 (td, J = 7.7, 4.9 Hz, 1H), 3.73 (s, 3H), 3.11 (d, J = 5.6 Hz, 2H), 
2.44 – 2.55 (m, 2H), 2.10 – 2.18 (m, 1H), 2.04 (s, 3H), 1.89 – 1.97 (m, 
1H); 13C NMR (126 MHz, CDCl3)  174.1, 173.0, 156.1, 142.6, 135.8, 
135.5, 129.3, 128.6, 128.5, 128.4, 128.3, 127.0, 67.3, 53.9, 52.4, 52.2, 
38.4, 29.8, 15.4; HRMS (ESI, +ve) C23H28N2O5S[M+Na]
+ calculated for 
467.1608, found 467.1606. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4-(methylthio)butyl]-
aminocarbonyl]-L-tryptophan methyl ester (15): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4-(methylthio)propyl] 
aminocarbonyl]-L-tryptophan methyl ester (15) (0.07 g, 0.15 mmol, 63%), 
white powder, was prepared following the same procedure as described 
for compound (4). 
1H NMR (500 MHz, CDCl3) 8.59 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.29 – 
7.41 (m, 4H), 7.15 – 7.21 (m, 3H), 7.09 (t, J = 7.5 Hz, 1H), 6.89 (s, 1H), 
5.81 (d, J = 8.9 Hz, 1H), 5.63 (d, J = 8.0 Hz, 1H), 5.03 (d, J = 12.2 Hz, 
1H), 4.87 (dt, J = 8.6, 5.2 Hz, 1H), 4.77 (td, J = 8.3, 4.8 Hz, 1H), 4.69 (d, 
J = 12.2 Hz, 1H), 3.64 (s, 3H), 3.30 (dd, J = 14.9, 5.1 Hz), 3.20 (dd, 
J = 14.9, 5.2 Hz), 2.40 – 2.47 (m, 2H), 2.00 – 2.10 (m, 4H),1.83 (dq, 
J = 14.5, 7.5 Hz); 13C NMR (126 MHz, CDCl3)  174.0, 173.1, 156.9, 
135.9, 135.0, 128.6, 128.5, 128.4, 127.4, 123.5, 122.0, 119.4, 118.4, 
111.4, 109.2, 67.5, 53.2, 52.3, 51.9, 32.4, 29.8, 28.0, 15.4; HRMS 
(ESI, +ve) C25H29N3O5S[M+Na]
+ calculated for 506.1717, found 506.1715. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4,4-(dimethyl)propyl] 
aminocarbonyl-L-phenylalanine methyl ester (16): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4,4-(dimethyl)propyl]aminocarbonyl]- 
L-pheny-lalanine methyl ester (16) (0.08 g, 0.18 mmol, 55%), white 
powder, was prepared following the same procedure as described for 
compound (4). 
1H NMR (500 MHz, CDCl3) 7.32 – 7.42 (m, 5H), 7.20 – 7.27 (m, 3H), 
7.07 – 7.12 (m, 2H), 5.20 (d, J = 12.3 Hz, 1H), 5.09 – 5.15 (m, 3H), 4.82 
(dt, J = 8.1, 5.5 Hz, 1H), 4.55 (td, J = 8.9, 5.2 Hz), 3.69 (s, 3H), 3.08 (t, 
J = 5.5 Hz, 2H), 1.63 – 1.71 (m, 1H), 1.58 (ddd, J = 13.6, 8.4, 5.2 Hz), 
1.44 (ddd, J = 13.5, 9.3, 5.7 Hz, 1H), 0.90 (dd, J = 8.2, 6.5 Hz, 6H); 13C 
NMR (126 MHz, CDCl3) 174.2, 172.9, 156.4, 135.9, 135.4, 129.4, 128.5, 
128.4, 128.3, 128.1, 127.0, 67.0, 53.9, 52.2, 51.6, 41.9, 38.5, 24.7, 22.8, 
21.8; HRMS (ESI, +ve) C24H30N2O5 [M+H]
+ calculated for 427.2227, 
found 427.2226. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4,4-(diemthyl)propyl]-
aminocarbonyl]-L-methionine methyl ester (17): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]-4,4-(diemthyl)propyl]aminocarbonyl]- 
L-methionine methyl ester (17) (0.10 g, 0.24 mmol, 40%), white powder, 
was prepared following the same procedure as described for compound 
(4). 
1H NMR (500 MHz, CDCl3) 7.31 – 7.43 (m, 5H), 5.12 – 5.23 (m, 3H), 
4.92 (d, J = 8.5 Hz, 1H), 4.61 (td, J = 7.7, 4.9 Hz, 1H), 4.54 (td, J = 8.9, 
5.2 Hz, 1H), 3.77 (s, 3H), 2.51 – 2.58 (m, 2H), 2.08 – 2.20 (m, 4H), 1.95 
(dq, J = 14.4, 7.4 Hz, 1H), 1.64 – 1.73 (m, 2H), 1.51 (ddd, J = 13.5, 9.2, 
5.7 Hz, 1H), 0.93 (dd, J = 6.5, 4.7 Hz, 6H); 13C NMR (126 MHz, CDCl3) 
 173.9, 173.4, 156.6, 135.4, 128.5, 128.3, 128.1, 67.0, 52.5, 52.3, 51.7, 
41.9, 32.2, 29.9, 24.7, 22.8, 21.9, 15.4; HRMS (ESI, +ve) C20H30N2O5S 
[M+Na]+ calculated for 411.1948, found 411.1946. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl](13C)aminocarbonyl]- 
L-tryptophan methyl ester (18): 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl](
13
C)aminocarbonyl]-L-tryptophan 
methyl ester (18) (0.70 g, 1.65 mmol, 90%), white powder, was prepared 
following the same procedure as described for compound (4). 13C 
labelled carbon dioxide, 13CO2, (carbon dioxide (
13C, 99 %) (< 1 % 18O) 
purchased from Cambridge Isotope Laboratories, Inc.) was used instead 
of CO2 derived from dry ice. 
1H NMR (500 MHz, CDCl3) 8.62 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.31 – 
7.35 (m, 4H), 7.19 – 7.22 (m, 2H), 7.16 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 
7.08 (ddd, J = 8.0, 7.0, 1.0 Hz, 1H), 6.87 (d, J = 2.4 Hz, 1H), 5.79 (dd, 
J = 8.5, 2.4 Hz, 1H), 5.65 (dd, J = 8.1, 2.4 Hz, 1H), 5.06 (d, J = 12.3 Hz, 
1H), 4.86 (dtd, J = 7.9, 5.2, 2.5 Hz, 1H), 4.70 (d, J = 12.3 Hz, 1H), 4.62 – 
4.68 (m, 1H), 3.62 (s, 3H), 3.28 (dd, 14.9, 5.2 Hz, 1H), 3.19 (dd, 14.9, 5.1 
Hz, 1H),1.31 (d, J = 7.3 Hz, 3H); 13C NMR (126 MHz, CDCl3)  175.1, 
173.3, 156.8, 135.9, 135.2, 128.5, 128.3, 128.1, 127.4, 123.6, 121.9, 
119.3, 118.4, 111.4, 109.2, 67.2, 53.1, 52.3, 48.5, 28.0, 19.1; HRMS 
(ESI, +ve) C22
13CH25N3O5 [M+Na]
+ calculated for 447.1756, found 
447.1755. 
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-tryptophan 
methyl ester using p-toluenesulfonyl chloride (4): General 
procedure using p-TsCl as activator. 
Dry ice was placed in a 500 ml round-bottom flask connected to a 
paraffin oil bubbler then to a drying tube containing pellets of 4 Å 
molecular sieves.  Using the Teflon tubing, CO2 (g) derived from dry ice 
was bubbled into a stirred, solution of L-alanine benzyl ester p-
toluenesulfonate salt (0.20 g, 0.57 mmol), 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (0.43 ml, 2.85 mmol) and pyridine (0.14 ml, 1.71 mmol) in 
anhydrous DCM (30 ml) at -20 C, for a period of 30 minutes whilst 
keeping the mixture at -20 C. Subsequently, a solution of 
p-toluenesulfonyl chloride (0.22 g, 1.14 mmol) in anhydrous DCM (5 ml) 
was added to the reaction over a period of 20 minutes under an 
atmosphere of argon. The reaction was then left stirring under an 
atmosphere of argon for 2 hours while it was allowed to warm up to room 
temperature. Upon addition of p-toluenesulfonyl chloride, the color of the 
reaction mixture gradually changed from clear to yellow as the reaction 
warms up to room temperature. Afterwards, the solvent was removed 
under reduced pressure and the brown, oily residue was dissolved in 
anhydrous pyridine (8 ml). Under an atmosphere of argon, a solution of L-
tryptophan methyl ester hydrochloride salt (0.15 g, 0.57 mmol) in 
anhydrous pyridine (2 ml) was added over a period of 10 minutes at room 
temperature. The mixture was left stirring under an atmosphere of argon 
at room temperature for 4 hours. The solvent was then removed under 
reduced pressure and the brown residue was dissolved in ethyl acetate 
(50 ml) and washed five times with a saturated sodium bicarbonate 
solution (40 ml). The organic layer was dried over magnesium sulfate, 
filtered, concentrated under reduced pressure and purified using flash 
chromatography (silica, hexane : ethyl acetate 3 : 1 to 1 : 1, 
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ninhydrin/UV) to yield the target compound (4) (0.08 g, 0.2 mmol, 35%) 
as a white powder.  
N-[[(1S)-1-[(Benzyloxy)carbonyl]ethyl]aminocarbonyl]-L-tryptophan 
methyl ester (4): General procedure using HATU as activator. 
Dry ice was placed in a 500 ml round-bottom flask connected to a 
paraffin oil bubbler then to a drying tube containing pellets of 4 Å 
molecular sieves.  Using the Teflon tubing, CO2 (g) derived from dry ice 
was bubbled into a stirred, solution of L-alanine benzyl ester p-
toluenesulfonate salt (0.20 g, 0.57 mmol), 1,8-diazabicyclo[5.4.0]undec-
7-ene (DBU) (0.43 ml, 2.85 mmol) and pyridine (0.14 ml, 1.71 mmol) in 
anhydrous DCM (30 ml) at -20 C, for a period of 30 minutes whilst 
keeping the mixture at -20 C. The reaction was allowed to warm up to 
room temperature and the solvent was removed under reduced pressure. 
The residue obtained was then dissolved in anhydrous DMF, (3 ml) and a 
solution of HATU (0.43 g, 1.14 mmol) in anhydrous DMF (1 ml) was 
added to the reaction followed by a solution of N,N-diisopropylethylamine, 
DIPEA (0.4 ml, 2.28 mmol) in anhydrous DMF (1 ml) under an 
atmosphere of argon. The reaction was then left stirring under an 
atmosphere of argon for 30 minutes. Subsequently, a solution of 
L-tryptophan methyl ester hydrochloride salt (0.15 g, 0.57 mmol) in 
anhydrous DMF (2 ml) was added over a period of 10 minutes at room 
temperature. The mixture was left stirring under an atmosphere of argon 
at room temperature for 4 hours. The solvent was then removed under 
reduced pressure and the brown residue was dissolved in ethyl acetate 
(50 ml) and washed five times with a saturated sodium bicarbonate 
solution (40 ml). The organic layer was dried over magnesium sulfate, 
filtered, concentrated under reduced pressure and purified using flash 
chromatography (silica, hexane : ethyl acetate 3 : 1 to 1 : 1, 
ninhydrin/UV) to yield the target compound (4)(0.11 g, 0.27 mmol, 48%) 
as a white powder.  
L-5-Bromotryptophan methyl ester (19): 
Acetyl chloride (0.20 ml, 2.80 mmol) was added over a period of 5 
minutes to a stirred solution of L-5-bromotryptophan (0.19 g, 0.70 mmol) 
in methanol (20 ml) at 0 °C. Following addition, the reaction mixture was 
allowed to warm up to room temperature then heated to reflux for 3 hours. 
When no trace of starting material remained (TLC: silica, methanol, 
ninhydrin, Rf 0.6), the solvent was removed under reduced pressure to 
leave L-5-bromotryptophan methyl ester (19) (0.20 g, 0.69 mmol, >95%), 
bright red solid. No further purification was required. 
1H NMR (500 MHz, CD3OD)  7.69 (s, 1H), 7.35 (d, J = 8.6 Hz, 1H), 7.22 
– 7.30 (m, 2H), 4.34 (t, J = 6.2 Hz, 1H), 3.82 (s, 3H), 3.35 – 3.50 (m, 2H); 
13C NMR (126 MHz, CD3OD)  169.3, 135.4, 128.6, 125.9, 124.2, 120.1, 
113.0, 112.0, 105.8, 53.1, 52.3, 25.8; HRMS (ESI, +ve) C12H13BrN2O2 
[M+H]+ calculated for 297.0226, found 297.0228. 
L-7-Iodotryptophan methyl ester (20): 
L-7-Iodotryptophan methyl ester (20)(0.09 g, 0.27 mmol, 92%), white 
powder, was prepared following the same procedure as described for 
compound (19). 
1H NMR (400 MHz, CD3OD)  7.56 (dd, J = 14.8, 7.6 Hz, 1H), 7.34 (s, 
1H), 6.88 (t, J = 7.6 Hz, 1H), 4.35 (apparent t, J = 6.1 Hz, 1H), 3.79 (s, 
3H), 3.42 (m, 2H); 13C NMR (101 MHz, CD3OD)  169.2, 138.6, 130.7, 
127.2, 125.3, 120.6, 117.8, 107.7, 75.7, 53.2, 52.4, 26.2; HRMS (ESI, 
+ve) C12H13IN2O2 [M+H]
+ calculated for 345.0094, found 345.0098. 
L-5-Chlorotryptophan methyl ester (21): 
L-5-Chlorotryptophan methyl ester (21)(0.12 g, 0.47 mmol, 94%), white 
powder, was prepared following the same procedure as described for 
compound (19). 
1H NMR (400 MHz, CD3OD)  7.54 (s, 1H), 7.38 (d, J = 8.6 Hz, 1H), 7.29 
(s, 1H), 7.12 (d, J = 7.9 Hz, 1H), 4.35 (t, J = 5.8 Hz, 1H), 3.82 (s, 3H), 
3.36 – 3.48 (m, 2H); 13C NMR (101 MHz CD3OD)  169.3, 135.2, 127.9, 
1206.0, 124.7, 121.6, 117.0, 112.5, 105.9, 53.1, 52.3, 25.9; HRMS (ESI, 
+ve) C12H13ClN2O2 [M+H]
+ calculated for 253.0738, found 253.0743. 
L-5-Fluorotryptophan methyl ester (22): 
L-5-Fluorotryptophan methyl ester (22)(0.10 g, 0.42 mmol, 94%), white 
powder, was prepared following the same procedure as described for 
compound (19). 
1H NMR (400 MHz, CD3OD)  7.34 – 7.41 (dd, J = 8.7, 4.1 Hz, 1H),  7.29 
(s, 1H), 7.19 – 7.25 (m, 1H), 6.93 (t, J = 9.1 Hz, 1H), 4.34 (t, J = 5.8 Hz, 
1H), 3.82 (s, 3H), 3.31 – 3.48 (m, 2H); 13C NMR (101 MHz, CD3OD) 
 169.3, 157.7 (d, J = 233.0 Hz), 133.4, 126.2, 124.8, 112.1 (d, 
J = 9.6Hz), 109.6 (d, J = 26.5 Hz), 106.3, 102.2 (d, J = 23.9 Hz), 53.1, 
52.3, 26.0; 19F NMR (377 MHz, CD3OD, decoupled 
1H)   -126.98; HRMS 
(ESI, +ve) C12H13FN2O2 [M+H]
+ calculated for 237.1034, found 237.1037. 
L-Methionine benzyl ester p-toluenesulfonate (23)33: 
To a stirred solution of L-methionine (0.20 g, 1.34 mmol) and 
p-toluenesulfonic acid (0.27 g, 1.60 mmol) in toluene (50 ml), a solution 
of benzyl alcohol (0.27 ml, 2.68 mmol) in toluene (10 ml) was added at 
room temperature over a period of 10 minutes. Following addition the 
mixture was set to reflux for 20 hours while fitted with a Dean-Stark 
apparatus to remove water. The reaction mixture was allowed to cool to 
room temperature, and then stored in the freezer for 3 h. The precipitate 
was filtered and washed with toluene to yield L-methionine benzyl ester 
p-toluenesulfonate salt (23) (0.35 g, 0.85 mmol, 75%) as a white solid. 
No further purification was required. 
1H NMR (500 MHz, CDCl3)  8.37 (s, 2H), 7.76 (d, J = 7.9 Hz, 2H), 7.18 – 
7.35 (m, 5H), 7.08 (d, J = 7.9 Hz, 2H), 5.13 (d, J = 12.2 Hz, 1H), 5.00 (d, 
J = 12.2 Hz, 1H), 4.18 (q, J = 5.9 Hz, 1H), 2.50 (dt, J = 14.6, 7.5 Hz, 1H), 
2.41 (dt, J = 13.9, 7.4 Hz, 1H), 2.31 (s, 3H), 2.12 (apparent hep, 
J = 6.6 Hz, 2H), 1.84 (s, 3H); 13C NMR (126 MHz, CDCl3)  168.9, 141.2, 
140.4, 134.7, 128.9, 128.5, 128.4, 128.3, 126.0, 67.9, 52.1, 29.4, 28.9, 
21.3, 14.8; HRMS (ESI, +ve) C12H17NO2S[M+H]
+ calculated for 240.1053, 
found 240.1050. 
L-Leucine benzyl ester p-toluenesulfonate (24)33: 
L-Leucine benzyl ester p-toluenesulfonate (24) (0.30 g, 0.76 mmol, 70%), 
white powderwas prepared following the same procedure as described 
for compound (23). 
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1H NMR (500 MHz, CDCl3)  8.37 (bs, 2H), 7.77 (d, J = 7.9 Hz, 2H), 7.25 
– 7.32 (m, 5H), 7.08 (d, J = 7.9 Hz, 2H), 5.12 (d, J = 12.3 Hz, 1H), 5.04 (d, 
J = 12.3 Hz, 1H), 3.97 (t, J = 6.9 Hz, 1H), 2.32 (s, 3H), 1.61 –1.74 (m, 
3H), 0.75 (dd, J = 7.7, 5.8 Hz, 6H); 13C NMR (126 MHz, CDCl3)  169.7, 
141.4, 140.2, 134.8, 128.8, 128.4, 128.3, 128.2, 126.1, 67.7, 51.7, 39.2, 
24.1, 22.0, 21.9, 21.3; HRMS (ESI, +ve) C13H19NO2  [M+H]
+ calculated 
for 222.1485, found 222.1483. 
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